Spectrum Pharma: The Labor Day Catalyst (NASDAQ:SPPI)
BioMedReports, the news portal covering the biomedical news and financial sector, in a special report, is reporting that Spectrum Pharmaceuticals (NASDAQ:SPPI) has an important FDA catalyst which may cause share prices to rise.
According to the special report by Justin Hall, this Labor Day, September 7, Spectrum Pharmaceuticals (NASDAQ:SPPI) expects an FDA decision for their non-Hodgkin’s lymphoma (NHL) radio-immunotherapeutic (RIT), Zevalin®.
The consensus held by most investors, analysts and commentators is that Zevalin will be approved as a first-line consolidation therapy for patients with NHL.
The new report appears today at BiomedReports.com:
Biotech investors interested in accessing the complete database of clinical trials and upcoming FDA decisions can access that information on the same site:
BiomedReports is not paid, compensated or incentivized in any way to report news about publicly traded companies.
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
- Contact Information
- M.E. Garza
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.